4-Cyan-2,5-dimethyl-pyridin | 7584-10-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-Cyan-2,5-dimethyl-pyridin
• 英文别名: 2,5-dimethyl-isonicotinonitrile；2,5-Dimethylisonicotinonitrile；2,5-dimethylpyridine-4-carbonitrile
• CAS: 7584-10-3
• 化学式: C₈H₈N₂
• 分子量: 132.165
• InChiKey: GCSJARUDMJJPLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Cyan-2,5-dimethyl-pyridin 在 palladium hydroxide on carbon 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、405.33 kPa 条件下， 反应 2.0h， 以56%的产率得到1-(2,5-dimethylpyridin-4-yl)methanamine hydrochloride
  参考文献：
  名称：

  WO2008/32204

  摘要：

  公开号：

文献信息

• LTA4 Hydrolase inhibitors
  申请人：G.D. SEARLE & CO.

  公开号：EP1221441A2

  公开（公告）日：2002-07-10

  The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.

  本发明提供了具有公式Ar1-Q-Ar2-Y-R-Z的化合物及其药用可接受的盐，其中Ar1和Ar2是可选地取代的芳基部分，Z是可选地取代的含氮部分，可以是环状、环状或双环状的胺，或可选地取代的单环或双环的含氮杂芳基部分；Q是能够连接两个芳基团的连接基团；R是烷基亚基；Y是能够连接芳基团和烷基亚基的连接基团，并且其中Z通过氮原子与R键合。本发明的化合物和药物组合物在治疗由LTB4产生介导的炎症性疾病中是有用的，例如银屑病、溃疡性结肠炎、炎症性肠病和哮喘。
• [EN] BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS<br/>[FR] DÉRIVÉS DE BIPYRIDINE-SULFONAMIDE POUR LE TRAITEMENT DE MALADIES ET D'AFFECTIONS NEURODÉGÉNÉRATIVES
  申请人：NOSCIRA SA

  公开号：WO2012069428A1

  公开（公告）日：2012-05-31

  The present invention relates to novel bipyridine sulfonamide derivatives of formula (I) and their use for the treatment and/or prophylaxis of a neurodegenerative disease or condition, particularly Alzheimers disease (AD), a cardiovascular disease or a pathology involving ischemia.. Additionally, processes for preparing such derivatives5 and pharmaceutical compositions comprising them are provided.

  本发明涉及公式（I）的新型双吡啶磺胺衍生物及其用于治疗和/或预防神经退行性疾病或症状，特别是阿尔茨海默病（AD）、心血管疾病或涉及缺血的病理的用途。此外，还提供了制备这种衍生物的方法和包含它们的药物组合物。
• SUBSTITUTED PYRIDYLMETHYL BICYCLICCARBOXYAMIDE COMPOUNDS
  申请人：Nagayama Satoshi

  公开号：US20090318497A1

  公开（公告）日：2009-12-24

  This invention provides a compound of the formula (I): wherein A 1 is N and A 2 is CR 7 , or A 1 is CR 7 and A 2 is N; Y 1 , Y 2 and Y 3 are each independently CH or N, Y 4 and Y 5 are each independently CR 8 or N, with the proviso that when one of Y 1 , Y 2 , Y 3 , Y 4 and Y 5 is N, the others are not N; R 1 and R 2 are each independently hydrogen, halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl or hydroxy(C 1 -C 6 )alkyl; R 3 and R 8 are each independently hydrogen, halogen, hydroxy, (C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl or (C 1 -C 6 )alkylsulfonyl; R 4 is halogen, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, halo(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkylsulfonyl, halo(C 1 -C 6 )alkylsulfinyl, halo(C 1 -C 6 )alkylthio, [(C 1 -C 6 )alkyl]NH— or [(C 1 -C 6 )alkyl] 2 N—; and R 5 , R 6 and R 7 are each independently hydrogen, halogen, (C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, or (C 1 -C 6 )alkoxy; or a pharmaceutically acceptable salt, solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了一种式（I）的化合物：其中A1为N且A2为CR7，或者A1为CR7且A2为N；Y1、Y2和Y3分别独立地为CH或N，Y4和Y5分别独立地为CR8或N，但是当Y1、Y2、Y3、Y4和Y5中的一个为N时，其他的不为N；R1和R2各自独立地为氢、卤素、（C1-C6）烷基、卤代（C1-C6）烷基或羟基（C1-C6）烷基；R3和R8各自独立地为氢、卤素、羟基、（C1-C6）烷基、羟基（C1-C6）氧烷基、（C1-C6）氧烷基-(C1-C6)烷基、（C1-C6）氧烷基-(C1-C6)氧烷基、卤代（C1-C6）烷基、（C1-C6）烷基硫醇基、（C1-C6）烷基亚砜基或（C1-C6）烷基磺酰基；R4为卤素、（C1-C6）烷基、（C3-C6）环烷基、卤代（C1-C6）烷基、羟基（C1-C6）烷基、卤代（C1-C6）氧烷基、羟基（C1-C6）氧烷基、（C1-C6）氧烷基-(C1-C6)烷基、（C1-C6）氧烷基-(C1-C6）氧烷基、卤代（C1-C6）烷基磺酰基、卤代（C1-C6）烷基亚砜基、卤代（C1-C6）烷基硫醇基、[(C1-C6)烷基]NH-或[(C1-C6)烷基]2N-；以及R5、R6和R7各自独立地为氢、卤素、（C1-C6）烷基、羟基（C1-C6）烷基或（C1-C6）氧烷基；或其药学上可接受的盐、溶剂。这些化合物对于治疗由VR1受体过度激活引起的疾病状况，例如哺乳动物中的疼痛等，是有用的。本发明还提供了包含上述化合物的制药组合物。
• Metal-free deoxygenative coupling of alcohol-derived benzoates and pyridines for small molecules and DNA-encoded libraries synthesis
  作者：Sai Rohini Narayanan Kolusu、Manuel Nappi

  DOI：10.1039/d2sc01621d

  日期：——

  Herein, we report a metal-free method for the deoxygenative coupling of alcohol-derived benzoates and pyridines promoted by visible light. Given the practical, mild and water-compatible conditions, small molecules and DNA headpieces can be successfully functionalized with a range of primary, secondary and tertiary alcohols. This protocol is distinguished by its wide substrate scope and broad applicability

  醇是天然丰富的生物相关有机化合物中最广泛存在的官能团之一，在许多情况下被视为原料化学品。在此，我们报告了一种在可见光促进下醇衍生的苯甲酸酯和吡啶脱氧偶联的无金属方法。考虑到实用、温和且与水相容的条件，小分子和 DNA 头件可以成功地用一系列伯醇、仲醇和叔醇进行功能化。该方案的特点是其底物范围广泛和适用性广泛，即使在后期功能化和 DNA-药物偶联反应的背景下也是如此。
• NOVEL BIPYRIDYL DERIVATIVES
  申请人：Sankio Chemical Co., Ltd.

  公开号：EP1231207A1

  公开（公告）日：2002-08-14

  Provided are novel specific dipyridyl derivatives as a useful substance or an intermediate in the fields of pharmaceuticals, agrichemicals, ligands, silver halide photosensitive materials, liquid crystals, surfactants, electrophotography and organic electroluminescence.

  本文提供了新型特异性二吡啶衍生物，可作为有用物质或中间体用于制药、农用化学品、配体、卤化银感光材料、液晶、表面活性剂、电致发光和有机电致发光领域。